{
  "meta": {
    "title": "Pancreas",
    "url": "https://brainandscalpel.vercel.app/pancreas-3fe83c6f.html",
    "scrapedAt": "2025-11-29T18:33:53.662Z"
  },
  "questions": [
    {
      "id": 3940,
      "choices": [
        {
          "id": 15739,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">GnRH agonist</span></span></span></p>"
        },
        {
          "id": 15740,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgen antagonist</span></span></span></p>"
        },
        {
          "id": 15741,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Selective estrogen receptor modulator</span></span></span></p>"
        },
        {
          "id": 15742,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Selective progesterone receptor modulator</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ulipristal is a relatively new drug being used by gynecologists. It acts as a?</span></span></span></p>",
      "unique_key": "Q4852686",
      "question_audio": null,
      "question_video": null,
      "map_id": 36123,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Selective progesterone receptor modulator</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ulipristal</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> acts as a <strong>Selective Progesterone Receptor Modulator (SPRM)</strong>. It is used in gynaecology for specific conditions such as the <strong>emergency contraception (30 mg single dose</strong> can be used up to <strong>120 hours of unprotected intercourse)</strong> and the treatment of <strong>moderate to severe symptoms of uterine fibroids</strong> in<strong> premenopausal women.</strong> As an<strong> SPRM,</strong> <strong>ulipristal</strong> works by <strong>modulating the</strong> <strong>progesterone receptors in the body,</strong> which can have <strong>both agonistic and antagonistic effects </strong>depending on the tissue. This action allows it to<strong> alter the endometrium,</strong> i<strong>nhibit or delay ovulation, </strong>and <strong>reduce the size </strong>and <strong>symptoms of uterine fibroids</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. GnRH agonist</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: GnRH agonists work by<strong> initially stimulating and then downregulating the production of gonadotropins (LH</strong> <strong>and FSH)</strong>, leading to a<strong> decrease in estrogen and testosterone production</strong>. Examples include <strong>leuprolide and goserelin</strong>. <strong>Ulipristal does</strong> <strong>not act </strong>through this<strong> mechanism.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Androgen antagonist</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Androgen antagonists <strong>block the effects of androgens (male hormones) at their receptor sites</strong>. They are used in conditions like<strong> prostate cancer and hirsutism in women.</strong> Ulipristal does not function as an androgen antagonist.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Selective estrogen receptor modulator</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: SERMs, such as<strong> tamoxifen or raloxifene,</strong> act on <strong>estrogen receptors</strong>, having <strong>agonistic or antagonistic effects depending on the target tissue</strong>. <strong>Ulipristal, </strong>however, specifically <strong>modulates progesterone receptors,</strong> <strong>not</strong> <strong>estrogen receptors.</strong></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective:</u></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ulipristal </strong>is a<strong> selective progesterone receptor modulator (SPRM)</strong> used in<strong> gynecology for emergency contraception </strong>and the treatment of<strong> uterine fibroids</strong>. Its unique <strong>action on progesterone receptors </strong>allows for <strong>versatile therapeutic effects</strong> in <strong>reproductive</strong> <strong>health.</strong></span></span></span></p>",
      "correct_choice_id": 15742,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3655,
      "choices": [
        {
          "id": 14599,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Linagliptin</span></span></span></p>"
        },
        {
          "id": 14600,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vildagliptin</span></span></span></p>"
        },
        {
          "id": 14601,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"color:black\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Exenatidie</span></span></span></span></p>"
        },
        {
          "id": 14602,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old hypertensive patient with stage 5 chronic kidney disease was diagnosed recently with Type 2 diabetes mellitus. He does not want to take injectable drugs. Which of the following oral hypoglycemic agents will be preferred in this patient that does not require any dose modification in renal failure?</span></span></span></p>",
      "unique_key": "Q8631194",
      "question_audio": null,
      "question_video": null,
      "map_id": 36119,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Linagliptin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Linagliptin </strong>is a <strong>dipeptidyl peptidase-4 (DPP-4) inhibitor </strong>that is preferred in patients with <strong>renal impairment</strong>, including those with <strong>stage 5 CKD</strong>, because it <strong>does not require dose adjustments</strong>. Linagliptin&#39;s pharmacokinetics are such that it is <strong>less dependent on renal excretion compared </strong>to <strong>other DPP-4 inhibitors, </strong>making it a <strong>safer </strong>option for patients with significant <strong>renal dysfunction</strong>. This characteristic allows for the management of<strong> Type 2 diabetes in patients with varying degrees of kidney disease </strong>without the need to modify the dose, thus simplifying<strong> treatment and reducing </strong>the <strong>risk of drug accumulation and adverse effects.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Vildagliptin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While<strong> vildagliptin </strong>is another<strong> DPP-4 inhibitor, </strong>it<strong> requires dose adjustments </strong>in patients with <strong>renal impairment</strong>, making it<strong> less ideal than linagliptin </strong>for patients with <strong>stage 5 CKD</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Exenatide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:<strong> Exenatide </strong>is <strong>not </strong>an <strong>oral hypoglycemic agent </strong>but an <strong>injectable glucagon-like peptide-1 (GLP-1) receptor agonist. </strong>It also <strong>requires dose adjustments </strong>in patients with <strong>renal impairment </strong>and would<strong> not </strong>be suitable for a patient who prefers to avoid injectable drugs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Metformin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Traditionally, <strong>metformin </strong>has been <strong>contraindicated in patients </strong>with significant<strong> renal impairment due to the risk of lactic acidosis</strong>. Although recent guidelines have provided<strong> more lenient criteria </strong>for its use in patients with <strong>moderate renal impairment</strong>, it is generally <strong>avoided in stage 5 CKD</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Linagliptin, a DPP-4 inhibitor, </strong>is a preferred <strong>oral hypoglycemic agent </strong>for patients with <strong>Type 2 diabetes and severe renal impairment</strong>, as it<strong> does not </strong>require dose adjustments in<strong> renal failure</strong>, simplifying <strong>diabetes management </strong>in this population.</span></span></span></p>",
      "correct_choice_id": 14599,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3962,
      "choices": [
        {
          "id": 15827,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liothyronine</span></span></span></p>"
        },
        {
          "id": 15828,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">L-Thyroxine</span></span></span></p>"
        },
        {
          "id": 15829,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carbimazole</span></span></span></p>"
        },
        {
          "id": 15830,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Steroids</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient presented with swelling in the neck as shown in figure. She also complained of decreased appetite, fatigue, cold intolerance, and menstrual irregularities. She gained 10 kg weight in the last 4-5 months. Thyroid function tests showed normal T4 levels but elevated TSH levels. The patient should be treated with. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture22.jpg\" style=\"height:227px; width:300px\" /></p>",
      "unique_key": "Q3132953",
      "question_audio": null,
      "question_video": null,
      "map_id": 36136,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. L-Thyroxine </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s clinical presentation and laboratory findings suggest hypothyroidism, characterized by swelling in the neck (likely indicating goitre), symptoms of decreased appetite, fatigue, cold intolerance, menstrual irregularities, weight gain, normal T4 levels, but elevated TSH levels. The appropriate treatment in this case would be L-thyroxine.</span></span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">L-Thyroxine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> (levothyroxine) is the standard treatment for hypothyroidism. It is a synthetic form of thyroxine (T4), the hormone that is deficient in hypothyroidism. Supplementation with L-Thyroxine helps to normalize thyroid hormone levels, thereby alleviating</strong> the symptoms of <strong>hypothyroidism</strong>, including those described for the <strong>patient. </strong>The<strong> goal of treatmen</strong>t is to <strong>normalize the patient&#39;s TSH levels and resolve symptoms.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Liothyronine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Liothyronine is a<strong> synthetic form of triiodothyronine (T3)</strong>. While it can be <strong>used </strong>in certain <strong>specific situations,</strong> such as in<strong> combination therapy with levothyroxine </strong>for some patients,<strong> L-Thyroxine </strong>remains the <strong>primary treatment</strong> for <strong>hypothyroidism</strong> due to its<strong> stability, longer half-life, and more consistent serum levels.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Carbimazole</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Carbimazole is used to <strong>treat hyperthyroidism, </strong>not hypothyroidism. It works by <strong>inhibiting the synthesis of</strong> <strong>thyroid hormones,</strong> which would be <strong>contraindicated in a patient </strong>already showing <strong>signs of low thyroid hormone activity.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Steroids</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Steroids are <strong>not a primary treatment for primary hypothyroidism</strong>. They can be used in <strong>specific cases of</strong> t<strong>hyroiditis</strong> where<strong> inflammation is a significant </strong>component, but they would <strong>not be the first choice i</strong>n typical hypothyroidism treatment.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with <strong>hypothyroidism </strong>indicated by symptoms of<strong> thyroid hormone deficiency </strong>and<strong> elevated TSH levels</strong> with <strong>normal T4, L-Thyroxine </strong>is the appropriate <strong>treatment </strong>to<strong> normalize thyroid function and alleviate symptoms.</strong></span></span></p>",
      "correct_choice_id": 15828,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3941,
      "choices": [
        {
          "id": 15743,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">To be given an empty stomach with a full glass of water.</span></span></span></p>"
        },
        {
          "id": 15744,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Must be taken along with food.</span></span></span></p>"
        },
        {
          "id": 15745,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Should be stopped if features of gastritis develop.</span></span></span></p>"
        },
        {
          "id": 15746,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Should be stopped if bone pains occur.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">What are the appropriate instructions to be given while prescribing bisphosphonates to a patient? </span></span></span></p>",
      "unique_key": "Q4977515",
      "question_audio": null,
      "question_video": null,
      "map_id": 36124,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. To be given empty stomach with a glass of water</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Bisphosphonates</strong> should be taken on an <strong>empty stomach with a full glass of water </strong>to enhance <strong>absorption</strong>. Patients are advised to remain <strong>upright (sitting or standing) for at least 30 to 60 minutes </strong>after taking the medication. This precaution <strong>helps to prevent</strong> <strong>esophageal irritation</strong> and <strong>ensure the drug moves quickly to the stomach, reducing the risk of gastroesophageal reflux </strong>and <strong>esophagitis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Must be taken along with food</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This instruction is<strong> incorrect</strong> because<strong> food</strong> significantly <strong>decreases the absorption of</strong> <strong>bisphosphonates.</strong> They <strong>should be taken</strong> on an<strong> empty stomach.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Should be stopped if features of gastritis develop</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While patients should report any<strong> severe gastrointestinal symptoms</strong> to their <strong>healthcare provider,</strong> the<strong> decision to stop </strong>the medication should be made<strong> by the physician.</strong> Management strategies may include evaluating the patient&#39;s condition, considering an <strong>alternative bisphosphonate formulation (e.g., intravenous),</strong> or<strong> addressing</strong> the <strong>gastritis </strong>while<strong> continuing treatment as necessary.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Should be stopped if bone pains occur</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Bone pain can be a <strong>side effect of bisphosphonates, </strong>but patients <strong>should consult</strong> their <strong>healthcare provider </strong>before <strong>stopping the medication</strong>. The provider may assess the <strong>cause of bone pain</strong> and consider <strong>alternative</strong> <strong>treatments or supportive</strong> measures rather than<strong> immediately discontinuing the bisphosphonate.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When prescribing<strong> bisphosphonates,</strong> it is<strong> crucial to instruct patients</strong> to take the medication on an<strong> empty stomach </strong>with <strong>plenty of</strong> <strong>water </strong>and to remain<strong> upright for</strong> at<strong> least 30 to 60 minutes</strong> afterward to <strong>prevent gastrointestinal complications</strong> and ensure <strong>optimal</strong> <strong>absorption of the drug.</strong></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> </span></span> </span></span></span></p>",
      "correct_choice_id": 15743,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4094,
      "choices": [
        {
          "id": 16355,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometriosis</span></span></span></p>"
        },
        {
          "id": 16356,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Male infertility</span></span></span></p>"
        },
        {
          "id": 16357,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Precocious puberty</span></span></span></p>"
        },
        {
          "id": 16358,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prostatic carcinoma</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-pulsatile administration of GnRH agonist can be used in all of the following conditions except.</span></span></p>",
      "unique_key": "Q2016109",
      "question_audio": null,
      "question_video": null,
      "map_id": 36137,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Male infertility </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">For treatment of <strong>male infertility,</strong> <strong>GnRH agonists</strong> need to be given in <strong>pulsatile manner. </strong>For all other conditions given in the options, <strong>GnRH agonists </strong>are administered in a <strong>non-pulsatile continuous fashion.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gonadotropin-Releasing Hormone (GnRH) and Its Analogs</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>GnRH is a decapeptide</strong> that stimulates <strong>gonadotropin release</strong> when it is secreted in a <strong>pulsatile pattern by the</strong> <strong>hypothalamus.&nbsp;</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Leuprolide&nbsp;</strong>was the <strong>first long-acting GnRH agonist. Other</strong> long-acting GnRH agonists include<strong>&nbsp;goserelin,&nbsp;histarelin,</strong> <strong>busurelin,&nbsp;nafarelin,&nbsp;and&nbsp;triptorelin.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Steady dosing (non-pulsatile) with these GnRH agonists inhibits gonadotropin </strong>release by <strong>downregulating GnRH</strong> receptors in th<strong>e pituitary cells </strong>that normally release <strong>gonadotropins. </strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulsatile administration of GnRH agonists is used for:</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypogonadotropic hypogonadism.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Infertility in both males (oligozoospermia) and females (anovulatory infertility)</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Delayed puberty</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Continuous GnRH agonist treatment is used:</span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">To suppress <strong>endogenous gonadotropin secretion </strong>in <strong>women</strong> undergoing<strong> ovulation induction with gonadotropin</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In women with <strong>gynecologic disorders</strong> that benefit from <strong>ovarian suppression (e.g., endometriosis, uterine leiomyomata)</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In men with <strong>advanced prostate cancer</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In children with <strong>central precocious puberty.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> first few days</strong> of <strong>continuous administration </strong>can<strong> temporarily exacerbate </strong>the condition. This is known as<strong> flare up reaction.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Endometriosis</strong>: <strong>Continuous GnRH agonist</strong> treatment can <strong>suppress ovarian function </strong>and is beneficial in conditions like <strong>endometriosis. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Precocious Puberty</strong>:<strong> GnRH agonists</strong> are used to suppress<strong> premature gonadotropin secretion</strong> in children with <strong>central</strong> <strong>precocious puberty. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Prostatic Carcinoma</strong>: In men with <strong>advanced prostate cancer,</strong> continuous<strong> GnRH agonist </strong>treatment is used to<strong> suppress</strong> <strong>androgen production.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Non-pulsatile administration of GnRH agonists</strong> is utilized for conditions requiring <strong>suppression of gonadotropin secretion</strong>, such as <strong>endometriosis, prostatic carcinoma, and precocious puberty, </strong>but<strong> not </strong>for <strong>male infertility</strong>, which requires <strong>pulsatile treatment</strong> to stimulate <strong>gonadotropin release.</strong></span></span></span></span></span></span></p>",
      "correct_choice_id": 16356,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3753,
      "choices": [
        {
          "id": 14991,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></span></span></p>"
        },
        {
          "id": 14992,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin</span></span></span></p>"
        },
        {
          "id": 14993,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol</span></span></span></p>"
        },
        {
          "id": 14994,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Linagliptin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient of diabetes mellitus and hypertension is admitted in the hospital with features of sepsis and there is increase in serum creatinine levels. Which of the following drugs should be stopped? </span></span></span></p>",
      "unique_key": "Q8843992",
      "question_audio": null,
      "question_video": null,
      "map_id": 36118,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Metformin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> should be<strong> stopped </strong>in this patient&rsquo;s case <strong>due to the development of sepsis and the increase in serum creatinine levels, </strong>which<strong> indicate an acute deterioration in renal function</strong>. Metformin is<strong> contraindicated </strong>in conditions that <strong>can impair renal function or lead to renal failure </strong>because of the <strong>risk of lactic acidosis</strong>, a rare but<strong> serious complication a</strong>ssociated with <strong>metformin accumulation </strong>in the body. In the setting of sepsis, which can further compromise <strong>renal function and increase the risk of lactic acidosis</strong>, <strong>discontinuation of metformin</strong> is advised until the patient&rsquo;s <strong>renal function stabilizes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Insulin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Insulin may still be needed to manage the patient&#39;<strong>s blood glucose levels, </strong>especially in the<strong> stress of sepsis</strong>, which can cause<strong> hyperglycemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Metoprolol</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: It is a<strong> lipid soluble beta-blocker </strong>used to manage<strong> hypertension </strong>and other <strong>cardiovascular conditions</strong>. It is <strong>safe </strong>in <strong>renal failure</strong>.<strong> Beta blockers</strong> which should be <strong>avoided in renal failure are atenolol, nadolol and sotalol (ANS) </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Linagliptin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A<strong> DPP-4 inhibitor </strong>used in the management of<strong> type 2 diabetes. </strong>It is considered safe in patients with <strong>renal impairment </strong>unlike other drugs in this group. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with <strong>diabetes and renal impairment, </strong>especially in <strong>acute settings such as sepsis,</strong><em> <strong>metformin </strong></em>should be discontinued to prevent the <strong>risk of lactic acidosis.</strong> It is important to<strong> monitor renal function </strong>closely and adjust medication as needed based on the patient&rsquo;s <strong>current health status.</strong></span></span></p>",
      "correct_choice_id": 14991,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4245,
      "choices": [
        {
          "id": 16957,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cortisol</span></span></span></p>"
        },
        {
          "id": 16958,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prednisolone</span></span></span></p>"
        },
        {
          "id": 16959,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Betamethasone</span></span></span></p>"
        },
        {
          "id": 16960,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydrocortisone</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Long term steroid therapy can lead to suppression of hypothalamic pituitary-adrenal axis. It can be overcome by using alternate day therapy with corticosteroids. Which of the following steroids is unsuitable for alternate day therapy for such purpose? </span></span></span></p>",
      "unique_key": "Q8334869",
      "question_audio": null,
      "question_video": null,
      "map_id": 36112,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Betamethasone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Betamethasone</strong> is a <strong>long-acting corticosteroid</strong> with a <strong>duration of action</strong> that generally exceeds <strong>48 hours. </strong>Because of its <strong>long</strong> d<strong>uration of action, </strong>betamethasone is<strong> unsuitable </strong>for <strong>alternate day</strong> therapy intended to <strong>minimize the suppression of the</strong> <strong>hypothalamic-pituitary-adrenal (HPA) axis.</strong> Alternate day therapy is designed to allow the <strong>HPA axis </strong>to <strong>recover on the off days,</strong> which is <strong>more feasible with corticosteroids</strong> that have a <strong>shorter duration of action.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Cortisol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Cortisol,</strong> also known as <strong>hydrocortisone</strong> when used as a medication, has a<strong> short duration of action, </strong>making it suitable for <strong>alternate day therapy.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Prednisolone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Prednisolone is an <strong>intermediate-acting corticosteroid </strong>that is commonly used in <strong>alternate day therapy to</strong> <strong>reduce HPA axis suppression.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hydrocortisone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hydrocortisone is <strong>essentially synthetic cortisol</strong> with a <strong>short duration of action</strong>, suitable for <strong>alternate day</strong> therapy to <strong>minimize HPA axis suppression.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Betamethasone&#39;s long duration of action</strong> makes it inappropriate for<strong> alternate day therapy </strong>designed to <strong>mitigate HPA axis</strong> <strong>suppression, </strong>unlike <strong>shorter-acting steroids like hydrocortisone</strong>, which are <strong>better </strong>suited for such <strong>treatment schedules.</strong></span></span></span></p>",
      "correct_choice_id": 16959,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4113,
      "choices": [
        {
          "id": 16431,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desmopressin:&nbsp; Treatment of diabetes insipidus.</span></span></span></p>"
        },
        {
          "id": 16432,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Octreotide:&nbsp; Treatment of bleeding esophageal varices.</span></span></span></p>"
        },
        {
          "id": 16433,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oxytocin:&nbsp; Induction of labor.</span></span></span></p>"
        },
        {
          "id": 16434,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Goserelin:&nbsp; Growth hormone deficiency</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following agents are correctly paired with an appropriate clinical use of the drug except.</span></span></span></p>",
      "unique_key": "Q9557041",
      "question_audio": null,
      "question_video": null,
      "map_id": 36110,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Goserelin: Growth hormone deficiency</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Goserelin </strong>is a<strong> gonadotropin-releasing hormone (GnRH) agonist,</strong> <strong>not </strong>used for the treatment of<strong> growth hormone deficiency</strong>. It is commonly used in the<strong> treatment of hormone-sensitive cancers </strong>such as <strong>prostate cancer in men and breast cancer in premenopausal women</strong>, as well as for<strong> endometriosis </strong>and in assisted reproduction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Desmopressin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Desmopressin is a <strong>synthetic analogue of vasopressin</strong> and is drug of choice for the treatment of <strong>central</strong> <strong>diabetes insipidus and nocturnal enuresis.</strong> It is also used for managing<strong> bleeding</strong> in patients<strong> with von Willebrand disease and mild hemophilia A </strong>due to its ability to<strong> increase the levels of von Willebrand factor and factor VIII</strong>.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Octreotide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Octreotide is a<strong> somatostatin analogue </strong>that can <strong>reduce portal blood flow </strong>and is <strong>used</strong> in the management of <strong>bleeding esophageal varices</strong> as an adjunct to specific treatments like <strong>endoscopic band ligation or sclerotherapy.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Oxytocin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Oxytocin is a <strong>peptide hormone </strong>and is<strong> drug of choice </strong>to<strong> induce labor in pregnant women</strong> who are <strong>at or near</strong> term when there is a medical reason for<strong> inducing labor, or to strengthen labor contractions during childbirth.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Goserelin </strong>is a <strong>GnRH agonist </strong>used primarily in the treatment of<strong> hormone-sensitive cancers </strong>and is<strong> not indicated for growth hormone</strong> <strong>deficiency,</strong> which would require<strong> growth hormone therapy </strong>or other <strong>specific treatments</strong> related to<strong> growth hormone biosynthesis or</strong> <strong>action.</strong></span></span></p>",
      "correct_choice_id": 16434,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3682,
      "choices": [
        {
          "id": 14707,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carbimazole</span></span></span></p>"
        },
        {
          "id": 14708,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lugol&rsquo;s iodine</span></span></span></p>"
        },
        {
          "id": 14709,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propylthiouracil</span></span></span></p>"
        },
        {
          "id": 14710,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methimazole</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old patient diagnosed with Graves&#39; disease is under consideration for antithyroid therapy. The patient has a history of atrial fibrillation and is currently on beta-blockers. Given the patient&#39;s clinical profile and the need to rapidly achieve euthyroidism while minimizing cardiac complications, the healthcare provider is exploring antithyroid medications that can not only reduce thyroid hormone production but also inhibit the peripheral conversion of thyroxine (T4) to the more active triiodothyronine (T3). Which of the following antithyroid medications can inhibit the peripheral conversion of T4 to T3?</span></span></span></p>",
      "unique_key": "Q6364365",
      "question_audio": null,
      "question_video": null,
      "map_id": 36122,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Propylthiouracil</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Propylthiouracil (PTU) </strong>is an <strong>antithyroid </strong>medication that<strong> not </strong>only <strong>inhibits thyroid hormone synthesis </strong>but also has the unique ability among <strong>antithyroid drugs to inhibit the peripheral conversion of thyroxine (T4) </strong>to the <strong>more active form</strong>, <strong>triiodothyronine (T3). </strong>This <strong>dual action </strong>can be particularly beneficial in managing <strong>hyperthyroidism </strong>in patients where <strong>rapid control of thyroid hormone effects </strong>is crucial, such as those with <strong>cardiac complications like atrial fibrillation. </strong>PTU&#39;s ability to<strong> reduce T3 levels </strong>can lead to a <strong>quicker normalization of thyroid hormone effects </strong>on the<strong> heart and other organs.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Carbimazole</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Carbimazole is a<strong> pro-drug </strong>that is<strong> converted to methimazole in the body</strong>. It <strong>inhibits thyroid hormone synthesis </strong>but <strong>does not </strong>significantly <strong>inhibit the peripheral conversion of T4 to T3.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Lugol&rsquo;s iodine</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Lugol&#39;s iodine can quickly<strong> reduce the size and vascularity of the thyroid gland </strong>and <strong>inhibit </strong>the release of <strong>thyroid hormones</strong>, but it does not have a direct inhibitory effect on the peripheral conversion of T4 to T3.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Methimazole</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Methimazole<strong> inhibits thyroid hormone synthesis </strong>by blocking the<strong> iodination of tyrosine </strong>residues in <strong>thyroglobulin</strong>. Like<strong> carbimazole</strong>, it<strong> does not </strong>significantly <strong>inhibit the peripheral conversion of T4 to T3.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture3.jpg\" style=\"height:562px; width:1000px\" /></span></span></u></strong></p>",
      "correct_choice_id": 14709,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4256,
      "choices": [
        {
          "id": 17001,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carcinoma of ovary</span></span></span></p>"
        },
        {
          "id": 17002,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometrial carcinoma</span></span></span></p>"
        },
        {
          "id": 17003,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Breast carcinoma</span></span></span></p>"
        },
        {
          "id": 17004,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic myeloid leukemia</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A lady who was treated for breast cancer is on long-term tamoxifen therapy as she is ER-positive. Drug tamoxifen can increase the risk for which of the following cancers?<strong> </strong></span></span></span></p>",
      "unique_key": "Q4932986",
      "question_audio": null,
      "question_video": null,
      "map_id": 36114,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Endometrial carcinoma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tamoxifen </strong>was the<strong> first&nbsp;selective estrogen receptor modulator (SERM)&nbsp;</strong>to be introduced. </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen is extensively used in the<strong> palliative treatment of breast cancer in postmenopausal women </strong>and is approved for<strong> chemoprevention of breast cancer</strong> in<strong> high-risk women. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen has <strong>estrogen agonistic action on bone and blood. Prevention </strong>of the expected <strong>loss of lumbar spine bone</strong> <strong>density </strong>and <strong>plasma lipid changes</strong> consistent with a <strong>reduction in the risk for atherosclerosis </strong>have also been reported in <strong>tamoxifen-treated patients </strong>following <strong>spontaneous or surgical menopause. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">However, this <strong>estrogen agonist activity on uterus</strong> may <strong>increase the risk of endometrial cancer.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a <strong>nonsteroidal agent</strong> that is given<strong> orally. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen has an initial <strong>half-life of 7&ndash;14 hours </strong>in circulation and is predominantly <strong>excreted by the liver. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Toremifene</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;is a <strong>structurally similar compound</strong> with very <strong>similar properties, indications, and toxicities.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Carcinoma of the ovary:</strong> There is<strong> no </strong>established link between <strong>tamoxifen use</strong> and an increased risk of ovarian cancer. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Breast carcinoma:</strong> <strong>Tamoxifen</strong> is actually used to<strong> reduce the risk of breast cancer</strong> recurrence. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Chronic myeloid leukemia:</strong> There is<strong> no</strong> evidence to suggest that<strong> tamoxifen increases the risk of developing leukemia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">While<strong> tamoxifen</strong> is effective in <strong>treating and preventing breast cancer</strong> recurrence in<strong> ER-positive patients</strong> by <strong>acting as an estrogen</strong> <strong>antagonist on breast tissue, </strong>its <strong>agonistic effects on the uterus</strong> can <strong>increase </strong>the risk of<strong> endometrial carcinoma, </strong>necessitating <strong>careful</strong> <strong>monitoring and evaluation during therapy.</strong></span></span></span></p>",
      "correct_choice_id": 17002,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4096,
      "choices": [
        {
          "id": 16363,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pramlintide</span></span></span></p>"
        },
        {
          "id": 16364,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></span></span></p>"
        },
        {
          "id": 16365,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sitagliptin</span></span></span></p>"
        },
        {
          "id": 16366,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glipizide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drug is approved for treatment of type 1 as well as type 2 diabetes mellitus?</span></span></span></p>",
      "unique_key": "Q8022585",
      "question_audio": null,
      "question_video": null,
      "map_id": 36106,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Pramlintide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pramlintide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is an <strong>amylin analogue</strong> approved for use in<strong> both type 1 and type 2 diabetes mellitus.</strong> It is used as an <strong>adjunct treatment</strong> for patients who are already using <strong>insulin </strong>but have <strong>not achieved</strong> desired <strong>glucose control. Pramlintide </strong>works by<strong> mimicking the</strong> <strong>actions of amylin&mdash;a hormone </strong>that is<strong> co-secreted </strong>with<strong> insulin from pancreatic &beta;-cells</strong>&mdash;thereby <strong>slowing gastric emptying, promoting</strong> <strong>satiety,</strong> and<strong> preventing postprandial spikes in blood glucose levels.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Metformin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Primarily used in the treatment of <strong>type 2 diabetes mellitus,</strong> metformin is a<strong> biguanide </strong>that <strong>reduces hepatic</strong> <strong>glucose production and improves insulin sensitivity. </strong>It is <strong>not used </strong>in the treatment of <strong>type 1 diabetes </strong>because type 1 diabetes involves <strong>insulin deficiency, </strong>and<strong> metformin does not replace insulin.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Sitagliptin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A <strong>dipeptidyl peptidase-4 (DPP-4) inhibitor</strong> used in the treatment of <strong>type 2 diabetes</strong>. It works by<strong> increasing</strong> <strong>incretin levels</strong>, which <strong>inhibit glucagon release and increase insulin secretion </strong>in a <strong>glucose-dependent</strong> manner.<strong> Sitagliptin </strong>is <strong>not</strong> approved for use in<strong> type 1 diabetes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Glipizide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A <strong>sulfonylurea</strong> used in the treatment of <strong>type 2 diabetes</strong>. It stimulates the <strong>release of insulin from pancreatic &beta;-cells</strong>. Because individuals with <strong>type 1 diabetes</strong> have little to <strong>no insulin production, sulfonylureas like glipizide </strong>are not effective for<strong> type 1 diabetes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Pramlintide</strong> is approved for<strong> both type 1 and type 2 diabetes </strong>as an <strong>adjunct to insulin therapy </strong>due to its role in <strong>modulating gastric</strong> <strong>emptying and blood glucose levels post meals.</strong></span></span> <span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> </span></span></span></span></span></p>",
      "correct_choice_id": 16363,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3700,
      "choices": [
        {
          "id": 14779,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Milnacipran</span></span></span></p>"
        },
        {
          "id": 14780,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teriparatide</span></span></span></p>"
        },
        {
          "id": 14781,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Strontium ranelate</span></span></span></p>"
        },
        {
          "id": 14782,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Denosumab</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drugs are used in treatment of osteoporosis except.</span></span></span></p>",
      "unique_key": "Q9494581",
      "question_audio": null,
      "question_video": null,
      "map_id": 36132,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Milnacipran</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Milnacipran</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is not used in the treatment of <strong>osteoporosis</strong>. It is a<strong> serotonin&ndash;norepinephrine reuptake inhibitor (SNRI)</strong> primarily used in the management of <strong>fibromyalgia and depression.</strong> It has <strong>no role</strong> in the management or treatment of <strong>osteoporosis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Teriparatide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Teriparatide is a <strong>recombinant form of parathyroid hormone</strong> used in the treatment of<strong> osteoporosis.</strong> It stimulates<strong> new bone formation </strong>by acting on <strong>osteoblasts</strong>, making it effective in <strong>reducing the risk of fractures </strong>in patients with <strong>osteoporosis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Strontium ranelate</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Strontium ranelate is a medication <strong>used to treat severe osteoporosis in postmenopausal women</strong> and <strong>men at high risk of fractures</strong>. It works by simultaneously <strong>decreasing bone resorption and increasing bone formation.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Denosumab</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Denosumab is a <strong>monoclonal antibody that inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-B</strong> <strong>Ligand)</strong>, a protein that<strong> acts</strong> as the <strong>primary signal for bone removal</strong>. <strong>By inhibiting RANKL,</strong> denosumab <strong>decreases bone resorption and</strong> <strong>increases bone mass and strength</strong> in patients with osteoporosis.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drugs Used for Osteoporosis </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture6.jpg\" style=\"height:226px; width:1000px\" /></p>",
      "correct_choice_id": 14779,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4107,
      "choices": [
        {
          "id": 16407,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Steroids</span></span></span></p>"
        },
        {
          "id": 16408,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alendronate</span></span></span></p>"
        },
        {
          "id": 16409,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyroxine</span></span></span></p>"
        },
        {
          "id": 16410,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Heparin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old postmenopausal woman presents to the clinic for a routine health check-up. She is concerned about osteoporosis, as her mother had a hip fracture at the age of 70. She has been on prednisone for the past year for rheumatoid arthritis and is also taking levothyroxine for hypothyroidism. She recently read about the risks of long-term medication use and osteoporosis. She inquiries about her medications and whether any of them could contribute to bone density loss. Which of her current medications is not associated with an increased risk of osteoporosis?</span></span></span></p>",
      "unique_key": "Q9588226",
      "question_audio": null,
      "question_video": null,
      "map_id": 36108,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Alendronate</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Alendronate is a bisphosphonate</strong> that is actually used to <strong>treat and prevent osteoporosis, </strong>not cause it. It works by<strong> inhibiting</strong> <strong>osteoclast-mediated bone resorption,</strong> leading to an overall<strong> increase in bone mass and strength.</strong> This medication is commonly prescribed for<strong> postmenopausal women at risk of osteoporosis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Steroids:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Long-term use of steroids,</strong> such as<strong> prednisone, </strong>is known to <strong>cause bone density loss and increase the risk of</strong> <strong>osteoporosis</strong> due to their<strong> impact on bone turnover and calcium absorption.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Thyroxine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Excessive levels of thyroid hormone</strong>, whether from <strong>hyperthyroidism or over-replacement</strong> with <strong>levothyroxine,</strong> can lead to<strong> increased bone resorption and a higher risk of osteoporosis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Heparin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Long-term use of heparin</strong> can interfere with <strong>bone formation and increase the risk of osteoporosis.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Alendronate</strong> is used to <strong>treat and prevent osteoporosis, </strong>whereas <strong>steroids, excess thyroxine, and heparin</strong> can contribute to the <strong>development of osteoporosis.</strong></span></span></span></span></span></p>",
      "correct_choice_id": 16408,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3621,
      "choices": [
        {
          "id": 14463,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desmopressin</span></span></span></p>"
        },
        {
          "id": 14464,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Leuprolide</span></span></span></p>"
        },
        {
          "id": 14465,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiazide diuretics</span></span></span></p>"
        },
        {
          "id": 14466,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Drug of choice for central diabetes Insipidus is.</span></span></span></p>",
      "unique_key": "Q7559444",
      "question_audio": null,
      "question_video": null,
      "map_id": 36116,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A. Desmopressin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Desmopressin</strong> is the<strong> drug of choice </strong>for the treatment of <strong>central diabetes insipidus. </strong>Central diabetes insipidus is a condition where the<strong> pituitary gland fails</strong> to secrete adequate amounts of <strong>antidiuretic hormone (ADH), </strong>also known as <strong>vasopressin, </strong>which <strong>helps</strong> the <strong>kidneys </strong>manage the<strong> amount of water in the body.</strong> <strong>Desmopressin</strong> is a <strong>synthetic analogue of vasopressin. </strong></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It acts selectively at<strong> V2</strong> <strong>receptors</strong> to <strong>increase urine concentration and decrease urine flow </strong>in a <strong>dose dependent manner.</strong> It is more resistant to degradation than<strong> endogenous vasopressin (Arginine vasopressin; AVP) </strong>and has a <strong>three to fourfold longer duration of action</strong>. <strong>Desmopressin </strong>can be given by <strong>IV or SC injection, nasal inhalation, or oral tablet.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B</span></strong><span style=\"font-size:12.0pt\">. <strong>Leuprolide</strong>: Leuprolide is a <strong>gonadotropin-releasing hormone (GnRH) agonist </strong>used in the treatment of <strong>hormone-sensitive</strong> conditions like<strong> prostate cancer, endometriosis, and uterine fibroids.</strong> It is <strong>not </strong>used in the treatment of<strong> diabetes insipidus</strong> as it does <strong>not </strong>influence <strong>ADH secretion or action.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C</span></strong><span style=\"font-size:12.0pt\">. <strong>Thiazide Diuretics</strong>: Thiazide diuretics are used in the treatment of <strong>both nephrogenic diabetes insipidus </strong>(a form of the condition caused by the <strong>kidneys&#39; inability to respond to ADH)</strong> as well as <strong>central (neurogenic) diabetes insipidus.</strong> They are drug of <strong>choice for nephrogenic diabetes insipidus</strong> but <strong>not central diabetes insipidus. </strong>Thiazides <strong>reduce urine volume </strong>in diabetes insipidus by <strong>increasing water absorption in the distal tubules </strong>of the kidney, but they <strong>do not</strong> address the <strong>lack of ADH production in central</strong> <strong>diabetes insipidus.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D</span></strong><span style=\"font-size:12.0pt\">. <strong>Insulin</strong>: Insulin is used in the<strong> treatment of diabetes mellitus, </strong>a completely<strong> different </strong>condition <strong>from diabetes insipidus.</strong> <strong>Diabetes mellitus</strong> involves problems with<strong> blood sugar control </strong>due to <strong>insufficient insulin production (Type 1 diabetes) </strong>or <strong>insulin</strong> <strong>resistance (Type 2 diabetes)</strong>. It <strong>does not </strong>directly affect the <strong>balance of water in the body, nor </strong>is it relevant to the <strong>treatment</strong> of <strong>diabetes insipidus.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/01/picture1_dSWDtRK.jpg\" style=\"height:176px; width:1000px\" /></span></span></u></strong></p>",
      "correct_choice_id": 14463,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3625,
      "choices": [
        {
          "id": 14479,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metyrapone</span></span></span></p>"
        },
        {
          "id": 14480,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketoconazole</span></span></span></p>"
        },
        {
          "id": 14481,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aminoglutethimide</span></span></span></p>"
        },
        {
          "id": 14482,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the above</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs can be used for medical adrenalectomy?</span></span></span></p>",
      "unique_key": "Q8360246",
      "question_audio": null,
      "question_video": null,
      "map_id": 36117,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. All the above</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Medical adrenalectomy </strong>refers to the pharmacological <strong>suppression of adrenal gland function,</strong> typically aimed at <strong>reducing </strong>the production of<strong> adrenal steroids</strong>. This approach is often<strong> used </strong>in the <strong>management of Cushing&#39;s syndrome, </strong>where there is an <strong>overproduction of cortisol</strong> by the <strong>adrenal glands. </strong>All the listed drugs, <strong>Metyrapone, Ketoconazole, and Aminoglutethimide,</strong> can be used for<strong> medical adrenalectomy.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Metyrapone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Inhibits 11-&beta;-hydroxylase,</strong> an enzyme critical in the<strong> final step of cortisol synthesis</strong> in the<strong> adrenal cortex</strong>. By <strong>inhibiting this enzyme</strong>, <strong>metyrapone</strong> effectively <strong>reduces cortisol</strong> production.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Ketoconazole:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Is an<strong> antifungal medication </strong>that also has <strong>potent inhibitory effects</strong> on <strong>adrenal and gonadal steroid synthesis.</strong> It works by <strong>inhibiting several cytochrome P450 enzymes</strong> involved in <strong>steroid synthesis,</strong> thereby <strong>reducing cortisol levels.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Aminoglutethimide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Inhibits </strong>the enzyme <strong>P450scc (cholesterol side-chain cleavage enzyme),</strong> which is involved in the<strong> first</strong> <strong>step of cortisol synthesis</strong>, converting <strong>cholesterol to pregnenolone</strong>. This results in a<strong> decrease in the production</strong> of all <strong>adrenal</strong> <strong>steroids</strong>, including <strong>cortisol.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">DRUGS INHIBITING THE FORMATION OF ADRENAL STEROIDS</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">These <strong>drugs</strong> can be used for <strong>medical adrenalectomy.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metyrapone</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketoconazole</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aminoglutethimide</span></span></span></li>\r\n\t<li><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mitotane</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/01/picture2.jpg\" style=\"height:494px; width:600px\" /></span></span></p>",
      "correct_choice_id": 14482,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3677,
      "choices": [
        {
          "id": 14687,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Posterior subcapsular cataract</span></span></span></p>"
        },
        {
          "id": 14688,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Iridocyclitis</span></span></span></p>"
        },
        {
          "id": 14689,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Open angle glaucoma</span></span></span></p>"
        },
        {
          "id": 14690,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Retinoblastoma</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old patient with a history of chronic uveitis has been on corticosteroid eye drops for an extended period as part of the treatment regimen. During a routine follow-up at the ophthalmology clinic, the ophthalmologist evaluates the patient for potential long-term complications associated with the prolonged use of corticosteroid eye drops. Which of the following is a complication of prolonged use of corticosteroid eye drops?</span></span></span></p>",
      "unique_key": "Q7149927",
      "question_audio": null,
      "question_video": null,
      "map_id": 36121,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Open angle glaucoma </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Open angle glaucoma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a recognized <strong>complication </strong>of prolonged use of <strong>corticosteroid eye drops</strong>. Corticosteroids can cause an <strong>increase in intraocular pressure (IOP) </strong>in some individuals. Over time, this <strong>elevated IOP can damage the optic nerve</strong>, leading to the <strong>development of open-angle glaucoma. </strong>This condition is characterized by the <strong>gradual loss of peripheral vision </strong>and,<strong> </strong>without<strong> </strong>appropriate management, <strong>can progress to blindness. </strong>It is crucial for patients on <strong>long-term corticosteroid eye drop </strong>therapy to have their<strong> IOP monitored </strong>regularly to detect any <strong>increase early and manage </strong>it accordingly<strong> to prevent optic nerve damage and preserve vision</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Posterior subcapsular cataract</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Although <strong>cataract formation, </strong>specifically posterior subcapsular cataracts, can occur with both<strong> systemic and prolonged topical corticosteroid use</strong>, the direct association is<strong> more </strong>commonly emphasized with <strong>systemic therapy</strong>. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Iridocyclitis</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is an <strong>inflammatory condition </strong>that<strong> corticosteroid eye drops aim to treat</strong>, rather than a side effect of their use.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Retinoblastoma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Retinoblastoma is a type of <strong>eye cancer</strong> unrelated to the use of corticosteroid eye drops. It is <strong>not a complication of corticosteroid therapy</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adverse effects of corticosteroids (</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">with prolonged use<strong> both </strong>as <strong>eye drops as well as systemic use</strong></span><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">G &ndash; G</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">laucoma (on topical use) </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">L &ndash; L</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">imb muscle atrophy </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">U &ndash; U</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">lcer (peptic ulcer) </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C &ndash; C</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ushing syndrome </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">O &ndash; O</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">steoporosis </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C &ndash; C</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ataract (on systemic use) </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">O &ndash; O</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">steonecrosis (avascular necrosis) </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">R &ndash;</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> C/I in <strong>R</strong>enal failure </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">T &ndash;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> C/I in <strong>T</strong>uberculosis (particularly ileo-caecal) </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">I &ndash; I</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">mpair healing. </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C &ndash;</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> C/I in <strong>C</strong>HF </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">O &ndash; O</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">edema </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">I &ndash; I</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">nfections (due to immune-suppressant action) </span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">D &ndash; D</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">iabetes mellitus </span></span></span></p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">S &ndash; S</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">uppression of HPA-axis</span></span></p>",
      "correct_choice_id": 14689,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3689,
      "choices": [
        {
          "id": 14735,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hepatic dysfunction</span></span></span></p>"
        },
        {
          "id": 14736,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Severe rash</span></span></span></p>"
        },
        {
          "id": 14737,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Agranulocytosis</span></span></span></p>"
        },
        {
          "id": 14738,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anaphylaxis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are potentially serious side effects of thioamide group of anti-thyroid drugs except?</span></span></span></p>",
      "unique_key": "Q3473227",
      "question_audio": null,
      "question_video": null,
      "map_id": 36128,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Anaphylaxis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Thioamides,</strong> such as <strong>methimazole and propylthiouracil, </strong>are <strong>antithyroid drugs</strong> used primarily in the treatment of <strong>hyperthyroidism. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Anaphylaxis is a severe,</strong> potentially<strong> life-threatening allergic reaction </strong>that can occur <strong>rapidly and affect the whole body.&nbsp;</strong>While <strong>allergic</strong> reactions can occur with <strong>any medication</strong>, <strong>anaphylaxis</strong> is <strong>not </strong>a commonly reported <strong>side effect of thioamides. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. </span></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hepatic dysfunction</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is a <strong>known serious side effect of thioamides,</strong> particularly<strong> propylthiouracil.</strong> Hepatic dysfunction can range from <strong>mild elevation of liver enzymes to severe liver injury and hepatic failure</strong>.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Severe rash</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>Dermatologic reactions, </strong>including severe<strong> rashes</strong>, can occur with <strong>thioamide drugs </strong>and can sometimes be serious enough to<strong> warrant discontinuation of the medication.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Agranulocytosis</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A <strong>serious and potentially life-threatening</strong> <strong>decrease</strong> in <strong>white blood cell count, </strong>specifically granulocytes, is a known <strong>side effect</strong> of <strong>thioamides</strong>.<strong> Agranulocytosis </strong>can lead to an<strong> increased risk of infections.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Given the options, the<strong> least likely serious side</strong> effect of thioamide antithyroid drugs is <strong>anaphylaxis</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Anaphylaxis </strong>is<strong> not </strong>a commonly reported <strong>side effect of thioamide antithyroid drugs,</strong> making it the <strong>least likely serious side effect</strong> among the options provided. Common serious side effects include<strong> hepatic dysfunction, severe rashes, and agranulocytosis.</strong></span></span><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\"> </span></span></span></p>",
      "correct_choice_id": 14738,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3943,
      "choices": [
        {
          "id": 15751,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acarbose</span></span></span></p>"
        },
        {
          "id": 15752,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></span></span></p>"
        },
        {
          "id": 15753,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glipizide</span></span></span></p>"
        },
        {
          "id": 15754,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Table sugar is not used in treating hypoglycemia secondary to?</span></span></span></p>",
      "unique_key": "Q9531872",
      "question_audio": null,
      "question_video": null,
      "map_id": 36126,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Acarbose</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acarbose</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is an <strong>alpha-glucosidase inhibitor</strong> that works by <strong>slowing down</strong> the <strong>digestion of carbohydrates</strong> in the intestine, thereby <strong>blunting the postprandial (after meal)</strong> rise in blood glucose levels. When<strong> hypoglycemia</strong> occurs <strong>secondary to acarbose use,</strong> table <strong>sugar (sucrose) is not</strong> effective for treating the <strong>hypoglycemia</strong> because <strong>acarbose inhibits the enzyme </strong>needed to <strong>break down sucrose</strong> <strong>into glucose</strong>, which can be <strong>absorbed and utilized</strong> by the body. Instead,<strong> glucose (dextrose) tablets or gel </strong>should be used to treat <strong>hypoglycemia </strong>in patients taking<strong> acarbose, as glucose does not </strong>require this <strong>enzymatic breakdown to be absorbed.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Metformin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Metformin primarily works by<strong> decreasing hepatic glucose production </strong>and <strong>improving insulin sensitivity</strong>. It <strong>does not </strong>directly cause<strong> hypoglycemia</strong> when used alone but can contribute to <strong>low blood sugar levels</strong> if used in combination with other antidiabetic drugs. <strong>Table sugar</strong> can be used to <strong>treat hypoglycemia</strong> <strong>secondary to metformin.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Glipizide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Glipizide is a <strong>sulfonylurea</strong> that <strong>stimulates insulin secretion from the pancreatic beta cells</strong>.<strong> Hypoglycemia </strong>caused by<strong> glipizide</strong> can be treated with<strong> table sugar,</strong> as it effectively <strong>raises blood glucose levels.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Insulin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: <strong>Insulin</strong> administration can<strong> lead to hypoglycemia</strong> if the dose is <strong>too high </strong>relative to the <strong>patient&#39;s insulin </strong>needs. <strong>Table sugar</strong> is effective in treating <strong>hypoglycemia </strong>secondary to<strong> insulin</strong> use because it quickly <strong>raises blood glucose levels.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The treatment of <strong>hypoglycemia </strong>in patients taking<strong> acarbose requires glucose (dextrose) </strong>rather than <strong>sucrose (table sugar) </strong>due to <strong>acarbose&#39;s mechanism of action on carbohydrate digestion.</strong></span></span></span></p>",
      "correct_choice_id": 15751,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3946,
      "choices": [
        {
          "id": 15763,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgen receptor antagonist</span></span></span></p>"
        },
        {
          "id": 15764,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">5-&alpha; reductase inhibitor</span></span></span></p>"
        },
        {
          "id": 15765,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">17-&alpha; hydroxylase inhibitor</span></span></span></p>"
        },
        {
          "id": 15766,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aromatase inhibitor</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mechanism of action of finasteride is?</span></span></span></p>",
      "unique_key": "Q3156259",
      "question_audio": null,
      "question_video": null,
      "map_id": 36129,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. 5-&alpha; reductase inhibitor</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Finasteride</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> acts as a <strong>5-&alpha; reductase inhibitor</strong>. This class of drugs <strong>inhibits the enzyme 5-&alpha; reductase</strong>, which is responsible for converting <strong>testosterone into dihydrotestosterone (DHT),</strong> a <strong>potent androgen</strong> involved in the development of<strong> benign prostatic</strong> <strong>hyperplasia (BPH) </strong>and <strong>male pattern baldness (androgenetic alopecia)</strong>. By reducing the<strong> production of DHT,</strong> <strong>finasteride helps in</strong> t<strong>reating these conditions.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Example:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Besides <strong>finasteride</strong>, another drug in this class is <strong>dutasteride</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Androgen Receptor Antagonist</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mechanism</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:<strong> Blocks androgens </strong>like <strong>testosterone and DHT</strong> from<strong> binding to their receptors</strong> in the body.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Example:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Flutamide</strong>, <strong>bicalutamide</strong>, and <strong>enzalutamide</strong> are used primarily in the<strong> treatment of prostate cancer </strong>by<strong> inhibiting</strong> the action of <strong>androgens at their receptor sites.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. 17-&alpha; Hydroxylase Inhibitor</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mechanism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Inhibits</strong> the enzyme<strong> 17-&alpha; hydroxylase,</strong> which is crucial in the <strong>biosynthesis of cortisol and androgens</strong> in the<strong> adrenal</strong> <strong>glands.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Example:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Ketoconazole</strong> (at high doses) can<strong> inhibit adrenal and gonadal steroid synthesis</strong> and is used <strong>off-label </strong>for this purpose, though it is primarily an<strong> antifungal medication.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Aromatase Inhibitor</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mechanism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Blocks</strong> the enzyme <strong>aromatase,</strong> which converts <strong>androgens into estrogens</strong>, thereby reducing <strong>estrogen levels.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Example:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Anastrozole</strong>, <strong>letrozole</strong>, and <strong>exemestane</strong> are aromatase <strong>inhibitors </strong>used in the treatment of <strong>estrogen receptor-positive</strong> <strong>breast cancer in postmenopausal women.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">DRUGS USED FOR BENIGN PROSTATIC HYPERPLASIA</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamsulosin:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>&nbsp;Alpha 1a-antagonist.</strong> <strong>Decreases</strong> <strong>smooth muscle tone of prostate and bladder neck</strong> which leads to <strong>improved urine flow</strong>, but it will <strong>not lead to reduction in size of prostate.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Finasteride:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> 5-alpha reductase (type II) inhibitor. </strong>Prevents conversion of<strong> testosterone to dihydrotestosterone (DHT)</strong>. DHT causes <strong>growth and differentiation in the prostate</strong>. <strong>Type 2 isoform </strong>of this enzyme is expressed by <strong>stromal cells in the prostate. Reduction </strong>in levels of <strong>DHT prevents further growth </strong>and sometimes reduces the <strong>size of the prostate </strong>as well.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Flutamide:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Oral<strong> nonsteroidal antiandrogen </strong>which <strong>inhibits androgen binding to its receptor.</strong> It is used in the treatment of <strong>metastatic prostatic cancer.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tadalafil:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Treatment with <strong>PDE-5 inhibitors</strong> can be considered in patients who have <strong>erectile dysfunction </strong>and <strong>mild or</strong> <strong>moderate symptoms of BPH</strong>. Tadalafil is approved by the <strong>FDA for use in BPH. </strong></span></span><strong> </strong></span></span><strong> </strong></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 15764,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3956,
      "choices": [
        {
          "id": 15803,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tolvaptan</span></span></span></p>"
        },
        {
          "id": 15804,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desmopressin</span></span></span></p>"
        },
        {
          "id": 15805,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">vW factor</span></span></span></p>"
        },
        {
          "id": 15806,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Terlipressin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is used for the treatment of syndrome of inappropriate secretion of ADH (SIADH)? </span></span></span></p>",
      "unique_key": "Q1680595",
      "question_audio": null,
      "question_video": null,
      "map_id": 36133,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Tolvaptan</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>ADH</strong> is secreted in response to <strong>hypovolemia, </strong>in which case<strong> its secretion is appropriate.</strong> However, if <strong>ADH is secreted in high quantities</strong> in presence of <strong>euvolemia or hypervolemia</strong>, it is called<strong> inappropriate secretion (SIADH).</strong> The<strong> resultant water retention</strong> can result in <strong>hyponatremia.</strong> Thus, <strong>SIADH</strong> is characterized by <strong>normovolemic or hypervolemic hyponatremia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Fluid restriction </strong>is treatment of <strong>choice for SIADH.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hypertonic saline (3% NaCl) + loop diuretics (depending upon volume status)</strong> is a treatment of choice for <strong>severe</strong> symptomatic<strong> hyponatremia.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Among drugs, <strong>tolvaptan (oral), conivaptan (IV) </strong>are preferred for <strong>long-term use.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tolvaptan</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a<strong> selective vasopressin V2 receptor antagonist </strong>used in the treatment of the <strong>syndrome of inappropriate secretion of</strong> <strong>antidiuretic hormone (SIADH)</strong>. By <strong>blocking the action </strong>of vasopressin at the<strong> V2 receptors in the renal collecting ducts,</strong> <strong>tolvaptan</strong> <strong>increases water excretion </strong>while sparing<strong> sodium, </strong>leading to an <strong>increase in serum sodium levels in patients with SIADH</strong>, where water r<strong>etention and dilutional hyponatremia </strong>are key problems.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Desmopressin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Desmopressin is a <strong>synthetic analog of antidiuretic hormone (ADH) </strong>used to treat conditions like <strong>central</strong> <strong>diabetes insipidus (where ADH is deficient),</strong> not SIADH, where<strong> ADH secretion is excessive.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. vW factor</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:<strong> Von Willebrand factor (vWF)</strong> concentrates are used in the treatment of<strong> Von Willebrand disease and certain</strong> <strong>types of hemophilia, </strong>not in the management of SIADH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Terlipressin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:<strong> Terlipressin</strong> is a<strong> synthetic analog of vasopressin </strong>used primarily in the treatment of <strong>esophageal variceal</strong> <strong>bleeding and hepatorenal syndrome,</strong> not SIADH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">For<strong> SIADH</strong>, where<strong> excessive ADH</strong> leads to<strong> water retention and hyponatremia,</strong> <strong>Tolvaptan</strong> is a valuable treatment option due to its <strong>selective action on V2 receptors</strong>, <strong>promoting the correction of sodium levels</strong> while avoiding the <strong>excessive loss of electrolytes.</strong></span></span></span></p>",
      "correct_choice_id": 15803,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3966,
      "choices": [
        {
          "id": 15843,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">1 and 4 correct.</span></span></span></p>"
        },
        {
          "id": 15844,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">2 and 3 correct.</span></span></span></p>"
        },
        {
          "id": 15845,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">1, 2, and 3 correct.</span></span></span></p>"
        },
        {
          "id": 15846,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">3 and 4 correct.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The effectiveness of oral contraceptives is reduced by?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Captopril</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Furosemide</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ampicillin</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rifampicin</span></span></span></span></span></li>\r\n</ol>",
      "unique_key": "Q2257481",
      "question_audio": null,
      "question_video": null,
      "map_id": 36131,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. 3 and 4 correct</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> effectiveness of oral contraceptives</strong> can be<strong> reduced</strong> by certain medications that affect their<strong> metabolism or absorption.</strong> Among the options listed:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ampicillin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A <strong>broad-spectrum penicillin antibiotic. </strong>Antibiotics like<strong> ampicillin </strong>can affect the <strong>gut flora</strong>. </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The normal <strong>gastrointestinal flora helps </strong>in the <strong>enterohepatic cycling (and bioavailability) of estrogens</strong>. Antimicrobial drugs like <strong>ampicillin</strong> that <strong>kill these organisms</strong> may <strong>reduce the efficacy of oral contraceptives. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rifampicin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A potent <strong>inducer of hepatic enzymes,</strong> particularly those involved in the <strong>metabolism of drugs. </strong>Rifampicin can significantly <strong>reduce the plasma levels of oral contraceptives </strong>by <strong>increasing their metabolism</strong>, thereby<strong> reducing their</strong> <strong>effectiveness</strong> and<strong> increasing the risk of contraceptive failure</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1. Captopril</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: An <strong>angiotensin-converting enzyme (ACE) inhibitor</strong> used to <strong>treat hypertension and heart failure</strong>. There is <strong>no</strong> evidence to suggest that <strong>captopril significantly affects </strong>the effectiveness of <strong>oral contraceptives.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">2. Furosemide</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A <strong>loop diureti</strong>c used in the treatment of <strong>edema and hypertension.</strong> Like <strong>captopril, frusemide does not</strong> have a known <strong>interaction</strong> that significantly <strong>reduces the effectiveness of oral contraceptives.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Therefore, the correct pairing is</span><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Option C. Ampicillin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> and</span><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> D. Rifampicin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> as<strong> both</strong> can <strong>reduce the effectiveness </strong>of <strong>oral contraceptives</strong> through <strong>different mechanisms</strong>&mdash;<strong>ampicillin</strong> through it<strong>s effect on gut flora </strong>and<strong> rifampicin</strong> through enzyme induction <strong>leading to</strong> <strong>increased metabolism of contraceptives.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Antibiotics</strong> like<strong> ampicillin</strong> and <strong>enzyme inducers </strong>like <strong>rifampicin</strong> can <strong>decrease the effectiveness of oral contraceptives. </strong></span></span></span></p>",
      "correct_choice_id": 15846,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4106,
      "choices": [
        {
          "id": 16403,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Isophane insulin</span></span></span></p>"
        },
        {
          "id": 16404,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin glargine</span></span></span></p>"
        },
        {
          "id": 16405,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin-zinc suspension</span></span></span></p>"
        },
        {
          "id": 16406,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin degludec</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin having the longest duration of action is?</span></span></span></p>",
      "unique_key": "Q4624156",
      "question_audio": null,
      "question_video": null,
      "map_id": 36107,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Insulin degludec</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Among the options listed, <strong>insulin degludec has the longest duration of action.</strong> It is a<strong> long-acting insulin analog </strong>designed to<strong> help</strong> <strong>control blood sugar levels throughout the day with a single dose</strong>. Its<strong> unique structure</strong> results in a <strong>prolonged duration of action,</strong> which can <strong>exceed 42 hours.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Isophane<strong> insulin (NPH)</strong>: <strong>Intermediate-acting insulin</strong> with an effective duration of <strong>10-20 hours</strong>, making it<strong> shorter in</strong> <strong>duration </strong>compared to <strong>insulin degludec.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option</span></strong> <strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">B</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Insulin glargine</strong>: Another<strong> long-acting insulin </strong>with a <strong>duration of approximately 24 hours, </strong>but <strong>still shorter than insulin</strong> <strong>degludec.</strong></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Insulin-zinc suspension (Lente)</strong>: Consists of <strong>30% amorphous and 70% crystalline insulin</strong>, classified as <strong>intermediate-acting</strong> with a <strong>duration similar to NPH.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Insulin Preparations</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture24.jpg\" style=\"height:424px; width:1000px\" /></span></strong></span></span></p>",
      "correct_choice_id": 16406,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4112,
      "choices": [
        {
          "id": 16427,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Raloxifene</span></span></span></p>"
        },
        {
          "id": 16428,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen</span></span></span></p>"
        },
        {
          "id": 16429,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ospemifene</span></span></span></p>"
        },
        {
          "id": 16430,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clomiphene citrate</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following SERM is approved for treatment of dyspareunia in post-menopausal females?</span></span></span></p>",
      "unique_key": "Q8289459",
      "question_audio": null,
      "question_video": null,
      "map_id": 36109,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Ospemifene</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ospemifene is a selective estrogen receptor modulator (SERM) </strong>that is approved for the <strong>treatment of dyspareunia,</strong> a symptom of <strong>vulvar and vaginal atrophy </strong>due to<strong> menopause</strong>. <strong>Ospemifene</strong> has <strong>estrogenic effects </strong>on the<strong> vaginal epithelium </strong>which help to <strong>relieve</strong> the<strong> symptoms</strong> associated with<strong> vaginal atrophy,</strong> such as <strong>pain during sexual intercourse.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Raloxifene:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Raloxifene is a <strong>SERM</strong> that is <strong>used primarily </strong>for the<strong> prevention and treatment of osteoporosis</strong> in <strong>postmenopausal women</strong> and to<strong> reduce the risk of invasive breast cancer</strong> in <strong>postmenopausal women</strong> with <strong>osteoporosis </strong>or at<strong> high</strong> risk for<strong> breast cancer</strong>. It is <strong>not used for dyspareunia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Tamoxifen:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Tamoxifen is used primarily in the <strong>treatment and prevention of breast cancer. </strong>While it has <strong>estrogen-like effects</strong> on certain tissues, it is <strong>not</strong> approved for the t<strong>reatment of dyspareunia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Clomiphene citrate:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Clomiphene citrate is used as a <strong>fertility medication to induce ovulation in women </strong>who do not ovulate, including those with <strong>polycystic ovary syndrome (PCOS)</strong>. It is<strong> not </strong>used for the <strong>treatment of dyspareunia.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ospemifene</strong> is the <strong>SERM, </strong>approved for the <strong>treatment of dyspareunia in postmenopausal women.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">SELECTIVE ESTROGEN RECEPTOR MODULATORS:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/03/picture1.jpg\" style=\"height:494px; width:1000px\" /></span></strong></span></span></p>",
      "correct_choice_id": 16429,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4119,
      "choices": [
        {
          "id": 16455,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin is inappropriate for initial management of type 2 diabetes.</span></span></span></p>"
        },
        {
          "id": 16456,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin decreases hepatic glucose production.</span></span></span></p>"
        },
        {
          "id": 16457,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin undergoes significant metabolism via the cytochrome enzymes.</span></span></span></p>"
        },
        {
          "id": 16458,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Weight gain is a common adverse effect.</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is true about metformin? </span></span></p>",
      "unique_key": "Q1695906",
      "question_audio": null,
      "question_video": null,
      "map_id": 36113,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Metformin decreases hepatic glucose production.</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option B:</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin is an <strong>oral antidiabetic medication </strong>commonly used as the<strong> first-line treatment for type 2 diabetes mellitus</strong>. It primarily works by <strong>decreasing hepatic glucose production,</strong> also known as<strong> gluconeogenesis</strong>, thereby<strong> reducing fasting blood glucose levels.</strong> Additionally, <strong>metformin increases insulin sensitivity</strong> and enhances <strong>peripheral glucose uptake, </strong>especially by <strong>skeletal muscle cells.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Metformin is inappropriate for initial management of type 2 diabetes:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is<strong> false.</strong> Metformin is considered the <strong>first-line therapy</strong> for the management of<strong> type 2 diabetes</strong> in the <strong>absence of contraindications.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Metformin undergoes significant metabolism via the cytochrome enzymes:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is<strong> false.</strong> Metformin is<strong> not</strong> metabolized by the cytochrome P450 enzyme system and is<strong> excreted unchanged in the urine.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Weight gain is a common adverse effect:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is<strong> false. </strong>Unlike some other<strong> diabetes medications, </strong>metformin is <strong>not associated with weight gain</strong> and is often chosen for its<strong> weight-neutral or weight-reducing effect.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Metformin </strong>is an effective<strong> first-line treatment for type 2 diabetes</strong> due to its<strong> ability to decrease hepatic glucose production,</strong> <strong>increase</strong> <strong>insulin sensitivity,</strong> and support <strong>peripheral glucose uptake</strong> <strong>without </strong>causing significant<strong> weight gain or undergoing metabolism </strong>by the <strong>liver&#39;s cytochrome P450 system.</strong></span></span> <span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"> </span></span></span></p>",
      "correct_choice_id": 16456,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4260,
      "choices": [
        {
          "id": 17017,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Does not stimulate insulin release.</span></span></span></p>"
        },
        {
          "id": 17018,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreases hepatic glucose production.</span></span></span></p>"
        },
        {
          "id": 17019,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Can be safely used in patients with renal dysfunction.</span></span></span></p>"
        },
        {
          "id": 17020,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Can be combined with sulfonylureas.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which one of the following statements about metformin is NOT true?</span></span></span></p>",
      "unique_key": "Q2690814",
      "question_audio": null,
      "question_video": null,
      "map_id": 36115,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Can be safely used in patients with renal dysfunction. </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Metformin,</strong> a<strong> biguanide </strong>class <strong>antidiabetic medication,</strong> is <strong>contraindicated in patients </strong>with <strong>renal dysfunction.</strong> The drug is primarily <strong>excreted by the kidney</strong>s, and <strong>impaired renal function </strong>can lead to an <strong>increased risk of a severe side effec</strong>t known as<strong> lactic acidosis.</strong> This condition is a <strong>build-up of lactic acid</strong> in the body, which can b<strong>e life-threatening</strong> if not managed promptly. Therefore, <strong>metformin</strong> must be <strong>used with caution </strong>or <strong>avoided in patients with reduced kidney function.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In addition to general restrictions for use of oral hypoglycemic agents, <strong>biguanides</strong> are <strong>contraindicated in hypotensive</strong> <strong>states, cardiovascular, respiratory, hepatic, and renal disease </strong>and in <strong>alcoholics</strong> because of <strong>increased risk of lactic</strong> <strong>acidosis.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>METFORMIN Decrease hepatic glucose </strong>production thereby<strong> reducing insulin resistance. </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It has <strong>no effect </strong>on <strong>insulin secretion</strong> by<strong> beta cells of pancreas.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin is the <strong>first line drug for type 2 DM </strong>and Can be<strong> combined with </strong>other oral hypoglycemic agents like <strong>sulfonylureas.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin can cause <strong>lactic acidosis</strong> as an adverse effect. It is <strong>contra-indicated </strong>in conditions that <strong>increase the risk </strong>of <strong>lactic acidosis</strong>. These include:</span></span></span>\r\n\t<ul>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiorespiratory insufficiency (Shock, respiratory disease)</span></span></span></strong></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal dysfunction</span></span></span></strong></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liver failure</span></span></span></strong></li>\r\n\t\t<li><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elderly</span></span></span></strong></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Does not stimulate insulin release:</strong> This statement is <strong>true.</strong> Metformin works by <strong>improving insulin sensitivity </strong>and <strong>decreasing glucose production in the liver </strong>rather than stimulating insulin release.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Decreases hepatic glucose production:</strong> This statement is <strong>true </strong>and describes one of the primary mechanisms of metformin&#39;s action. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Can be combined with sulfonylureas:</strong> This statement is <strong>true</strong>. <strong>Metformin</strong> is often used in <strong>combination </strong>with <strong>sulfonylureas</strong> to <strong>enhance glucose control in patients with type 2 diabetes.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While <strong>metformin is a first-line treatment for type 2 diabetes,</strong> its use must be<strong> carefully </strong>considered in patients with<strong> renal dysfunction</strong> due to the<strong> increased risk of lactic acidosis, </strong>a serious and <strong>potentially fatal condition</strong></span></span></span></span></span></p>",
      "correct_choice_id": 17019,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23768,
      "choices": [
        {
          "id": 95037,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recombinant PTH [rPTH]</span></span></span></p>"
        },
        {
          "id": 95038,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recombinant calcitonin</span></span></span></p>"
        },
        {
          "id": 95039,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recombinant insulin</span></span></span></p>"
        },
        {
          "id": 95040,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Recombinant prolactin</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teriparatide is a drug used in osteoporosis that acts by stimulation of osteoblasts. It is?</span></span></span></p>",
      "unique_key": "Q7532149",
      "question_audio": null,
      "question_video": null,
      "map_id": 36120,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Recombinant PTH [rPTH]</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teriparatide</span></span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is a recombinant preparation of<strong> 1&ndash;34 molecules of amino terminal of human PTH.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It<strong> acts</strong> by <strong>stimulating osteoblasts.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It needs to be given by <strong>subcutaneous injection once daily.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It has been found to<strong> increase bone mineral density</strong> in <strong>osteoporotic women.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Its use is recommended for a <strong>period of 2 years.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment with <strong>teriparatide </strong>should be <strong>followed by bisphosphonate therapy.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It <strong>increases the risk of development of osteosarcoma.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Recombinant calcitonin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is<strong> incorrect</strong> as calcitonin is a hormone that primarily <strong>helps regulate calcium levels </strong>by <strong>inhibiting osteoclast activity</strong>, thereby <strong>reducing bone resorption.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Recombinant insulin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect.</strong> Insulin is a hormone related to <strong>glucose metabolism</strong>,<strong> not </strong>directly involved in<strong> bone</strong> <strong>metabolism.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Recombinant prolactin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong>. <strong>Prolactin</strong> is a hormone primarily involved in <strong>lactation</strong> and has <strong>no direct therapeutic</strong> application in <strong>osteoporosis treatment.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Teriparatide</strong>, a <strong>recombinant form of PTH,</strong> is a <strong>unique treatment for osteoporosis </strong>that<strong> stimulates osteoblasts to increase bone</strong> <strong>formation</strong>. Due to its <strong>mode of action and associated risks</strong>, it is used <strong>selectively and typically followed</strong> by treatment with <strong>bisphosphonates </strong>to <strong>consolidate the gains</strong> in <strong>bone density.</strong></span></span></span></span></span></span></p>",
      "correct_choice_id": 95037,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3961,
      "choices": [
        {
          "id": 15823,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Octreotide</span></span></span></p>"
        },
        {
          "id": 15824,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Levo-thyroxine</span></span></span></p>"
        },
        {
          "id": 15825,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cabergoline</span></span></span></p>"
        },
        {
          "id": 15826,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pegvisomant</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only oral drug effective for treatment of condition shown in figure is?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture20.jpg\" style=\"height:383px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q4148344",
      "question_audio": null,
      "question_video": null,
      "map_id": 36135,
      "difficulty_level": "difficult",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Cabergoline</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The figure illustrates the features of<strong> Acromegaly,</strong> which is characterized by the <strong>coarsening of facial features,</strong> <strong>enlargement of the</strong> h<strong>ands and feet, goiter, </strong>and <strong>other systemic </strong>manifestations. Acromegaly is often due to a <strong>growth hormone-secreting pituitary</strong> <strong>adenoma.</strong> The only <strong>oral drug effective</strong> for the treatment of Acromegaly as listed is <strong>Cabergoline,</strong> which is a <strong>dopamine D2 receptor</strong> <strong>agonist</strong>. It<strong> reduces</strong> the release of<strong> growth hormone </strong>and is effective in<strong> controlling the disease.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Octreotide</strong> is <strong>incorrect</strong> because it is an <strong>injectable somatostatin analog </strong>used in the treatment of<strong> Acromegaly. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Levo-thyroxine</strong> is<strong> incorrect </strong>because it is used to <strong>treat hypothyroidism</strong> and has no therapeutic role in the treatment of Acromegaly. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Pegvisomant</strong> is <strong>incorrect </strong>because it is an <strong>injectable growth hormone receptor antagonist</strong> used for <strong>Acromegaly</strong> but is <strong>not</strong> an <strong>oral medication.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DRUGS FOR ACROMEGALY</span></span></strong></span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture21.jpg\" style=\"height:288px; width:1000px\" /></span></span></strong></span></span></strong></span></span></p>",
      "correct_choice_id": 15825,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4243,
      "choices": [
        {
          "id": 16949,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Afrezza can be used as a replacement for injectable insulin.</span></span></span></p>"
        },
        {
          "id": 16950,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glargine is never mixed with other insulins because of its acidic pH.</span></span></span></p>"
        },
        {
          "id": 16951,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Degludec is a long-acting subcutaneous depot insulin.</span></span></span></p>"
        },
        {
          "id": 16952,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lente is a mixture of 70% crystalline and 30% amorphous insulin.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following statements about insulin preparations are correct except?</span></span></span></p>",
      "unique_key": "Q5878441",
      "question_audio": null,
      "question_video": null,
      "map_id": 36111,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Afrezza can be used as a replacement for injectable insulin.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Afrezza, a short-acting inhaled insulin, </strong>is primarily utilized to manage<strong> blood glucose levels at meal times</strong> and is characterized by a <strong>rapid onset</strong> and <strong>short duration of action</strong>. While it helps<strong> control postprandial blood sugar spikes,</strong> it<strong> does not</strong> serve as a <strong>standalone</strong> <strong>treatment </strong>and must be used in <strong>conjunction with long-acting injectable insulin</strong> to ensure stable <strong>basal glucose control</strong> throughout the day.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">B.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Glargine is never mixed with other insulins because of its acidic pH:</strong> This statement is <strong>correct.</strong> Insulin glargine has an <strong>acidic pH of about 4,</strong> which can cause <strong>precipitation</strong> when <strong>mixed with other insulins,</strong> hence it should <strong>not be mixed</strong> with them.</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Degludec is a long-acting subcutaneous depot insulin:</strong> This statement is<strong> correct. Insulin degludec</strong> provides a<strong> long-acting</strong> <strong>basal insulin effect </strong>due to its<strong> unique formulation t</strong>hat allows it to form a depot after<strong> subcutaneous injection, releasing insulin</strong> <strong>steadily over 24 hours or longer.</strong></span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Lente is a mixture of 70% crystalline and 30% amorphous insulin:</strong> This statement is<strong> correct</strong>. <strong>Lente insulin </strong>is composed of <strong>70% crystalline insulin, </strong>which provides a <strong>longer-acting effect</strong>, and <strong>30% amorphous insulin,</strong> which <strong>acts more quickly, </strong>making it a <strong>mixed intermediate-acting insulin.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Afrezza </strong>is <strong>not </strong>a full replacement for <strong>injectable insulin; </strong>it is used to supplement<strong> long-acting insulin </strong>therapies by managing<strong> acute</strong> <strong>meal time blood sugar increases</strong> in patients with diabetes.</span></span></span></span></span></span></p>",
      "correct_choice_id": 16949,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3684,
      "choices": [
        {
          "id": 14715,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bromocriptine- Treatment of precocious puberty</span></span></span></p>"
        },
        {
          "id": 14716,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Octreotide- treatment of diarrhea associated with vasoactive intestinal peptide tumors.</span></span></span></p>"
        },
        {
          "id": 14717,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desmopressin- treatment of diabetes insipidus</span></span></span></p>"
        },
        {
          "id": 14718,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Leuprolide- treatment of infertility</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following pairs of drugs and its indications is matched incorrectly?</span></span></span></p>",
      "unique_key": "Q4428648",
      "question_audio": null,
      "question_video": null,
      "map_id": 36125,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Bromocriptine- Treatment of precocious puberty</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Bromocriptine</strong> is primarily used for the treatment of <strong>hyperprolactinemia, acromegaly, and type 2 diabetes mellitus.</strong> It is<strong> not</strong> indicated for the treatment of<strong> precocious puberty</strong>, where <strong>GnRH analogs like leuprolide </strong>are the <strong>appropriate therapy</strong>. <strong>Bromocriptine&#39;s </strong>mechanism involves<strong> dopamine agonism</strong>, which <strong>inhibits prolactin secretion </strong>but <strong>does no</strong>t play a role in the management of <strong>precocious puberty,</strong> which typically involves <strong>suppressing premature sexual hormone production.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Octreotide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Correctly</strong> matched. Octreotide, an <strong>octapeptide analog of somatostatin, </strong>is effective in reducing the <strong>severe</strong> <strong>secretory diarrhea</strong> associated with conditions like<strong> carcinoid syndrome and vasoactive intestinal peptide tumors (VIPomas).</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Desmopressin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Correctly</strong> matched. Desmopressin is used in the management of<strong> central diabetes insipidus, nocturnal</strong> <strong>enuresis, and von Willebrand&rsquo;s disease.</strong> It acts by <strong>mimicking vasopressin</strong>, thus helping control <strong>urine production </strong>and <strong>improving</strong> <strong>blood clotting factors.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Leuprolide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Correctly matched</strong> when considering its use in <strong>reproductive health.</strong> Leuprolide, a<strong> GnRH analog</strong>, can be administered in a<strong> pulsatile</strong> fashion to treat conditions like <strong>anovulatory infertility</strong>, which relies on <strong>stimulating follicular development and ovulation.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bromocriptine: </span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Used for treatment of <strong>hyperprolactinemia, acromegaly, and type 2 diabetes mellitus.</strong></span></span></span></span></span></span></p>",
      "correct_choice_id": 14715,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3959,
      "choices": [
        {
          "id": 15815,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Canagliflozin</span></span></span></p>"
        },
        {
          "id": 15816,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exenatide</span></span></span></p>"
        },
        {
          "id": 15817,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pramlintide</span></span></span></p>"
        },
        {
          "id": 15818,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vildagliptin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Based on the mechanism shown in figure. Drug X is likely to be?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/02/picture18.jpg\" style=\"height:153px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q3246588",
      "question_audio": null,
      "question_video": null,
      "map_id": 36134,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Vildagliptin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The image describes the <strong>pathway of incretin activation </strong>and its effect on<strong> insulin and glucagon release. Drug X</strong> is illustrated as <strong>inhibiting the enzyme DPP-4 (Dipeptidyl peptidase-4), </strong>which normally <strong>breaks down active GLP-1 (Glucagon-like peptide-1).</strong> By preventing this <strong>breakdown</strong>, Drug <strong>X increases the levels of active GLP-1, </strong>which in turn <strong>increases insulin release and decreases</strong> <strong>glucagon release from the pancreas.</strong> <strong>Vildagliptin </strong>is a known DPP-4 inhibitor, which aligns with the mechanism depicted.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Canagliflozin</strong> is <strong>incorrect</strong> because it is an<strong> SGLT-2 inhibitor,</strong> which promotes <strong>glucosuria</strong> by <strong>preventing glucose reabsorption</strong> <strong>in the renal tubules,</strong> which is unrelated to the DPP-4 inhibition pathway. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exenatide</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is<strong> incorrect</strong> because it is a <strong>GLP-1 analogu</strong>e that mimics the<strong> action of GLP-1 to stimulate insulin release </strong>but does not inhibit DPP-4. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Pramlintide</strong> is<strong> incorrect</strong> because it is an <strong>amylin analogue</strong>, which has a different mechanism of action involving the <strong>modulation of gastric emptying and promotion of satiety;</strong> it does not inhibit DPP-4.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Vildagliptin </strong>is a<strong> DPP-4 inhibitor </strong>that enhances the action of <strong>incretins by preventing the breakdown of active GLP-1,</strong> leading to <strong>increased insulin release and decreased glucagon release</strong>, which helps to <strong>control blood glucose levels </strong>in <strong>diabetes mellitus.</strong></span></span></span></p>",
      "correct_choice_id": 15818,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3967,
      "choices": [
        {
          "id": 15847,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is used as an adjuvant in the treatment of estrogen receptor positive breast cancer.</span></span></span></p>"
        },
        {
          "id": 15848,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It reduces the risk of osteoporosis.</span></span></span></p>"
        },
        {
          "id": 15849,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It has a beneficial effect on lipid profile by increasing HDL/LDL cholesterol ratio.</span></span></span></p>"
        },
        {
          "id": 15850,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It reduces the risk of endometrial carcinoma.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following statements about tamoxifen are true except.</span></span></span></p>",
      "unique_key": "Q1757098",
      "question_audio": null,
      "question_video": null,
      "map_id": 36138,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. It reduces the risk of endometrial carcinoma.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tamoxifen</strong> is a <strong>selective estrogen receptor modulator (SERM) </strong>that has<strong> complex effects</strong> on various tissues. While it acts as an <strong>estrogen receptor antagonist</strong> in<strong> breast tissue,</strong> which is beneficial in the <strong>treatment of estrogen receptor-positive breast cancer,</strong> it paradoxically has an <strong>estrogen agonist effect on the endometrium. </strong>This agonistic action can potentially <strong>increase the risk of</strong> <strong>endometrial carcinoma.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Adjuvant in Estrogen Receptor-Positive Breast Cancer</strong>:<strong> True,</strong> <strong>tamoxifen </strong>is commonly used as an<strong> adjuvant therapy for</strong> <strong>estrogen receptor-positive breast cancer</strong> due to its <strong>antagonistic effects </strong>on the <strong>estrogen receptor in breast tissue. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Risk of Osteoporosis</strong>: <strong>True,</strong> <strong>tamoxifen</strong> has an <strong>estrogen agonistic action</strong> on bone, leading to an <strong>antiresorptive effect</strong> that can <strong>reduce the risk of osteoporosis. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Effect on Lipid Profile</strong>: <strong>True, tamoxifen </strong>is associated with <strong>improvements in lipid profiles</strong>, as it <strong>decreases total and LDL</strong> <strong>cholesterol</strong> <strong>without </strong>significantly affecting <strong>HDL and triglyceride levels.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen is a <strong>SERM</strong> that has<strong> estrogen agonistic action on bone, blood (lipid profile) and liver </strong>whereas it <strong>acts as</strong> <strong>estrogen receptor antagonist in breast and endometrium.&nbsp; </strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is indicated as an<strong> adjuvant in the treatment of estrogen receptor positive breast cancer.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is associated with <strong>reduced risk of cancer in the contralateral breast.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tamoxifen </strong>also <strong>decreases total and LDL cholesterol</strong> without any change in HDL and triglyceride level. It thus has favorable effect on lipid profile by <strong>increasing the HDL/LDL cholesterol ratio</strong>.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It also <strong>improves the bone mass due to antiresorptive effect,</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen is <strong>effective orally.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It has <strong>biphasic plasma t&frac12; (10 hrs. and 7 days)</strong> and<strong> long duration of action.</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Hot flushes</strong> and<strong> nausea and vomiting</strong> occur in <strong>25% of patients, </strong>and many other <strong>minor adverse effects</strong> are observed.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tamoxifen</strong> increases the <strong>risk of endometrial carcinoma and thromboembolic events.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It <strong>causes retinal deposits</strong>, <strong>decreased visual acuity and cataracts</strong> in occasional patients&rdquo; </span></span> </span></span></span></li>\r\n</ul>",
      "correct_choice_id": 15850,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3945,
      "choices": [
        {
          "id": 15759,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is an inhalational insulin preparation.</span></span></span></p>"
        },
        {
          "id": 15760,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">By using afreeza, meal-time injectable bolus insulin requirement is not there.</span></span></span></p>"
        },
        {
          "id": 15761,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is given in multiple doses.</span></span></span></p>"
        },
        {
          "id": 15762,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is used in combination with short acting insulin.</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All are true regarding insulin &#39;AFREZZA&#39; except?</span></span></p>",
      "unique_key": "Q5034497",
      "question_audio": null,
      "question_video": null,
      "map_id": 36130,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. It is used in combination with short acting insulin.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Afrezza</strong>, being a <strong>rapid-acting insulin itself, </strong>is generally <strong>not</strong> used in <strong>combination with other short-acting insulin preparations.</strong> It may be used along with<strong> long-acting insulin</strong> types in some treatment plans, particularly for individuals with<strong> type 1 diabetes, to ensure</strong> <strong>stable baseline glucose control.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. It is an inhalational insulin preparation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>True. </strong>Afrezza is administered via inhalation, offering an <strong>alternative to injectable</strong> <strong>insulin</strong> forms for <strong>rapid-acting control of blood glucose levels.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. By using Afrezza, meal-time injectable bolus insulin requirement is not there:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Generally<strong> true</strong>. Afrezza <strong>replaces the need&nbsp;</strong></span></span></span><span style=\"font-family:Calibri,sans-serif; font-size:12pt\">for<strong> meal-time injectable insulin</strong> in many cases. However, some patients might still require an<strong> injectable form</strong> depending on their <strong>specific glucose control</strong> needs and<strong> diabetes management plan.</strong></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. It is given in multiple doses:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> True.</strong> Afrezza is taken at the<strong> start of each meal</strong>, thus it is administered<strong> multiple times</strong> <strong>throughout the day </strong>depending on the<strong> number of meals consumed.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Afrezza</strong> is an<strong> innovative inhalational insulin </strong>that provides<strong> rapid-acting blood glucose control </strong>and can potentially<strong> reduce or eliminate</strong> the need for <strong>meal-time injectable insulin. </strong>It is<strong> not </strong>typically <strong>combined with other short-acting insulins</strong>, making <strong>option D</strong> <strong>the false statement </strong>in the context of this query.</span></span></p>",
      "correct_choice_id": 15762,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3688,
      "choices": [
        {
          "id": 14731,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Saxagliptin</span></span></span></p>"
        },
        {
          "id": 14732,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Linagliptin</span></span></span></p>"
        },
        {
          "id": 14733,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vildagliptin</span></span></span></p>"
        },
        {
          "id": 14734,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sitagliptin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs can be given in renal failure safely?</span></span></span></p>",
      "unique_key": "Q8716558",
      "question_audio": null,
      "question_video": null,
      "map_id": 36127,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Linagliptin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients with<strong> type 2 diabetes mellitu</strong>s have dysfunction in <strong>incretin hormones (such as glucagon-like peptide-1 or GLP-1</strong> and <strong>glucose-dependent insulinotropic polypeptide or GIP).</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">By<strong> inhibiting the dipeptidyl peptidase-4 (DPP-4)</strong> enzyme, it is possible to <strong>slow</strong> the <strong>inactivation of GLP-1 and GIP,</strong> promoting<strong> blood glucose level decrease </strong>in a glucose-dependent manner.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Linagliptin</strong> is a <strong>dipeptidyl peptidase-4 inhibitor (DPP IV inhibitor)</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Linagliptin</strong> is approved for the treatment of<strong> type 2 diabetes mellitus</strong> as an<strong> anti-hyperglycemic agent </strong>that can be used as <strong>monotherapy or in combination </strong>with other medications <strong>(metformin, sulphonylurea, pioglitazone, metformin plus</strong> <strong>sulfonylurea or insulin).</strong></span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Most gliptins</strong> are avoided in <strong>renal failure except linagliptin.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Saxagliptin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Generally<strong> requires dose adjustments</strong> or is <strong>avoided in patients with renal failure </strong>due to its <strong>renal excretion </strong>and potential for accumulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Vildagliptin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Similar to saxagliptin</strong>, it typically<strong> requires dose modifications i</strong>n patients with<strong> renal impairment</strong> to prevent adverse effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Sitagliptin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Also <strong>primarily eliminated renally,</strong> and thus <strong>needs dose adjustment</strong> in patients with <strong>renal dysfunction to avoid</strong> <strong>potential toxicity.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Linagliptin </strong>is a preferred choice among <strong>dipeptidyl peptidase-4 inhibitors </strong>for patients with<strong> renal failure </strong>due to its <strong>pharmacokinetic</strong> profile that allows <strong>safe use without the need for dosage adjustments </strong>in this population.</span></span></span></span></span></span></p>",
      "correct_choice_id": 14732,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}